Treatment of obesity and essential hypertension and related disorders

• US 5,280,014 A
• Filed: 07/18/1991
• Issued: 01/18/1994
• Est. Priority Date: 01/11/1988
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Leighton, Brendan, Cooper, Garth J. S.
• Primary Examiner(s): Lee, Lester L.
• Application Number:
  US07/737,794
• Time in Patent Office: 915 Days
• Field of Search: 514/12-17, 514/4
• US Class Current: 514/6.8
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/225 Calcitonin gene related peptide
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors

Abstract

The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.

Claims

1. A method for enhancing glycogen synthesis in a subject comprising administering to said subject an amount of an amylin antagonist effective to reduce amylin activity in said subject.

5. The method of any of claims 1, 2, 3, or 4 wherein said amylin antagonist is deamidated amylin.

6. The method of any claims 1, 2, 3, or 4 wherein said amylin antagonist is reduced amylin.

7. The method of any of claims 1, 2, 3, or 4 wherein said amylin antagonist comprises a biologically subactive subpeptide of amylin.

8. The method of any of claims 1, 2, 3, or 4 wherein said amylin antagonist is Ser² Ser⁷ amylin.

9. The method of claim 7 wherein said amylin subpeptide comprises amylin 8-37.

10. The method of any of claims 1, 2, 3 or 4 wherein said amylin antagonist comprises a biologically subactive subpeptide of CGRP.

11. The method of any of claims 1, 2, 3 or 4 wherein said amylin antagonist comprises an anti-amylin antibody.

12. The method of claim 10 wherein said CGRP subpeptide comprises CGRP 8-37.

2. A method for the treatment of obesity in a subject comprising administering to said subject an amount of an amylin antagonist effective to reduce amylin activity in said subject.

3. A method for increasing the rate of incorporation of glucose into glycogen in mammalian muscle comprising administering to said mammal an amount of an amylin antagonist effective to reduce amylin activity in said mammal.

4. A method for the treatment of essential hypertension in a subject comprising administering to said subject an amount of an amylin antagonist effective to reduce amylin activity in said subject.